ANIMAL vaccine developer Imugene has finalised a $5 million share placement it announced on November 23.
The funds were raised from institutional and sophisticated investors and will be used to speed up commercialisation of Imugene’s lead products: the RMT preventative product for post weaning diarrhoea in pigs, its two pig disease preventative vaccines and the Poultry Productivity Enhancer.
The placement comprised 20 million shares at 25 cents each and four million new options exercisable at 50 cents on or before January 31 2007.